BURLINGTON, Ontario, December 17, 2024--(BUSINESS WIRE)--Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN ® ...

With this approval, DYSPORT THERAPEUTIC now has the broadest label of all approved botulinum neurotoxins for spasticity, which includes both upper and lower limb spasticity in adults, as well as lower ...

Allergan announced that the Food and Drug Administration (FDA) has approved Botox (onabotulinumtoxinA) for the treatment of lower limb spasticity in adults to decrease the severity of increased muscle ...

The treatment was already approved for pediatric upper limb spasticity earlier this year. This new approval was based on data from a phase 3 trial evaluating the safety and efficacy of Botox in 381 ...

Study design: Before-After trial measured prior to cold air therapy, immediately following, after 30 and 60 min. Objective: To determine the effect of cold air therapy in relieving spasticity, the ...

UK regulators have issued a green light for the use of Botox (botulinum type A) to treat ankle disability in patients who have suffered a stroke. UK regulators have issued a green light for the use of ...

DUBLIN, Jan. 22, 2016 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX® ...

BOSTON and PARIS, Sept. 27, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc., (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the ...

In the United States, someone has a stroke every 40 seconds.[i] Though stroke death rates have declined in recent decades, it is a leading cause of serious long-term disability,[ii] taking a toll on ...